tiprankstipranks
Trending News
More News >
CytoMed Therapeutics Limited (GDTC)
:GDTC
US Market
Advertisement

CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

Compare
14 Followers

Top Page

GDTC

CytoMed Therapeutics Limited

(NASDAQ:GDTC)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
$2.50
▼(-7.06% Downside)
The overall stock score for GDTC is primarily impacted by its poor financial performance, with significant revenue declines and cash flow challenges. While technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends weigh heavily on the valuation. The absence of earnings call insights and corporate events leaves the financial and technical aspects as the primary drivers of the score.

CytoMed Therapeutics Limited (GDTC) vs. SPDR S&P 500 ETF (SPY)

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company DescriptionCytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
How the Company Makes MoneyCytoMed Therapeutics generates revenue through multiple streams, including the commercialization of its proprietary therapies and technologies, licensing agreements with pharmaceutical companies, and partnerships with research institutions. The company may receive upfront payments, milestone payments based on the progress of clinical trials, and royalties on sales from licensed products. Additionally, funding from government grants and collaborations with industry partners contribute to its financial stability. Significant partnerships with key players in the biotech industry also enhance its research capabilities and market reach, thereby driving further revenue growth.

CytoMed Therapeutics Limited Financial Statement Overview

Summary
The company faces significant financial challenges, with declining revenues, persistent losses, and cash flow deficits. Despite a strong equity position relative to debt, the need for improved cash management and revenue generation is critical.
Income Statement
30
Negative
The income statement reveals significant challenges, with the company experiencing a decline in total revenue from $290,560 in 2023 to $52,005 in 2024, indicating a negative revenue growth rate. Additionally, the net income remained negative, with a considerable net loss of $1,883,178 in 2024, reflecting poor profitability and a concerning net profit margin.
Balance Sheet
45
Neutral
The balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, resulting in a low debt-to-equity ratio. However, the reduction in total assets and stockholders' equity from 2023 to 2024 highlights potential risks and financial instability.
Cash Flow
35
Negative
The cash flow statement indicates negative operating cash flow, with a substantial free cash flow deficit of $2,742,350 in 2024. While the company had a significant capital expenditure in 2024, the free cash flow remains negative, pointing to cash management challenges and the need for more efficient cash utilization.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue258.16K52.01K290.56K0.0084.18K44.92K
Gross Profit283.14K52.38K381.92K-81.03K81.59K41.43K
EBITDA-2.05M-1.79M-2.94M-1.10M-1.05M-776.21K
Net Income-2.79M-1.88M-3.13M-2.27M-1.53M-1.47M
Balance Sheet
Total Assets6.57M7.37M9.37M3.90M4.51M2.89M
Cash, Cash Equivalents and Short-Term Investments2.25M3.64M6.82M1.18M1.87M703.20K
Total Debt385.05K339.20K339.50K3.15M2.42M2.26M
Total Liabilities892.51K749.76K852.28K3.46M2.59M2.53M
Stockholders Equity5.62M6.57M8.52M438.24K1.92M360.37K
Cash Flow
Free Cash Flow-2.24M-3.01M-2.72M-1.40M-1.70M-828.43K
Operating Cash Flow-1.79M-1.98M-2.68M-1.04M-1.27M-643.14K
Investing Cash Flow1.62M494.59K-2.11M-353.37K-610.72K-371.94K
Financing Cash Flow-50.50K-33.36K8.16M793.25K3.09M1.44M

CytoMed Therapeutics Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.69
Price Trends
50DMA
2.05
Positive
100DMA
2.05
Positive
200DMA
2.26
Positive
Market Momentum
MACD
0.14
Negative
RSI
56.28
Neutral
STOCH
33.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Positive. The current price of 2.69 is above the 20-day moving average (MA) of 2.22, above the 50-day MA of 2.05, and above the 200-day MA of 2.26, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 56.28 is Neutral, neither overbought nor oversold. The STOCH value of 33.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GDTC.

CytoMed Therapeutics Limited Risk Analysis

CytoMed Therapeutics Limited disclosed 106 risk factors in its most recent earnings report. CytoMed Therapeutics Limited reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

CytoMed Therapeutics Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$28.04M-42.29%-21.99%
44
Neutral
$24.13M-112.22%
44
Neutral
$26.65M-88.27%32.57%
33
Underperform
$23.71M-0.55-129.46%64.35%
31
Underperform
$19.83M-183.72%20.28%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GDTC
CytoMed Therapeutics Limited
2.39
-0.17
-6.64%
AKTX
Akari Therapeutics
0.74
-1.66
-69.17%
MTVA
MetaVia
0.98
-1.87
-65.61%
LPTX
Leap Therapeutics
0.48
-3.67
-88.43%
PASG
Passage Bio
7.14
-6.15
-46.28%
KAPA
Kairos Pharma, Ltd.
1.09
-0.35
-24.31%

CytoMed Therapeutics Limited Corporate Events

CytoMed Therapeutics’ Chairman Boosts Stake Amid Biotherapeutics Growth
Oct 22, 2025

On October 22, 2025, CytoMed Therapeutics Limited announced that its Executive Chairman, Mr. Peter Choo, has increased his shareholding in the company by purchasing an additional 105,824 shares, bringing his total effective holdings to 21.95%. Mr. Choo’s decision reflects confidence in the company’s proprietary technologies and the growing interest in biotherapeutics in Asia, particularly in China. This move is seen as a strategic positioning within the expanding Southeast Asian healthcare market, which offers unique opportunities due to rising healthcare costs in the West and a supportive regulatory environment.

CytoMed Therapeutics Bids for TC BioPharm’s Assets Amid Strategic Expansion
Oct 14, 2025

On October 14, 2025, CytoMed Therapeutics Limited announced a cash bid for the acquisition of potentially synergistic assets from TC BioPharm Limited, which entered administration on October 2, 2025. This acquisition aims to enhance CytoMed’s expertise in allogeneic cell therapies for cancer treatment, potentially accelerating its commercialization timeline and expanding its mission to provide affordable therapeutic options globally. This move represents CytoMed’s second acquisition in a year, following its purchase of a licensed cord blood bank in Malaysia in 2024, which supports its strategic expansion into new therapeutics.

CytoMed Therapeutics Unveils Promising AML Therapy Research
Oct 2, 2025

On October 2, 2025, CytoMed Therapeutics Limited announced a significant advancement in their research collaboration with The University of Texas, MD Anderson Cancer Center. The publication of their preclinical study highlights the potential of CytoMed’s allogeneic γδ T cell therapy for treating acute myeloid leukemia (AML), marking a promising step forward in developing ‘off-the-shelf’ immunotherapy solutions. This development is expected to pave the way for further clinical trials in Southeast Asia, potentially offering new treatment options for patients with limited alternatives, thereby strengthening CytoMed’s position in the biopharmaceutical industry.

CytoMed Therapeutics Reports Increased Revenue Amidst Financial Challenges
Sep 30, 2025

On September 30, 2025, CytoMed Therapeutics Limited released its unaudited interim condensed consolidated financial statements for the six months ending June 30, 2025. The company reported a significant increase in revenue to S$155,887 compared to the previous year. However, the financial results also showed a comprehensive loss of S$2,269,263, reflecting ongoing challenges in the company’s financial performance. The announcement provides insights into the company’s operational challenges and financial health, which could impact its market positioning and stakeholder confidence.

CytoMed Therapeutics Expands into Auto-immune Diseases with Cord Blood Biotech
Aug 28, 2025

On August 28, 2025, CytoMed Therapeutics Limited announced the successful expansion of clinical-scale natural killer (NK) cells from cord blood units, marking a significant step in their strategic reorganization. The company plans to establish a new cord blood-derived biotech under LongevityBank Pte Ltd, which will focus on autologous therapies, while CytoMed will continue to develop allogeneic therapies. This move aims to create new revenue streams and growth opportunities, leveraging their recent acquisition of a licensed cord blood bank in Malaysia. The acquisition provides access to valuable cord blood resources, enhancing CytoMed’s capabilities in developing therapeutics for autoimmune diseases and cancers. The company also plans to spin off LongevityBank as a standalone entity, further expanding its market presence.

CytoMed Therapeutics Launches ATM Offering Program to Boost Growth
Aug 19, 2025

On August 18, 2025, CytoMed Therapeutics Limited announced the initiation of an At-the-Market (ATM) offering program through a sales agreement with R.F. Lafferty & Co., Inc. This agreement allows CytoMed to sell ordinary shares worth up to $4,304,945, with the proceeds intended for general corporate purposes, including business diversification, development initiatives, and potential acquisitions. The announcement highlights the company’s strategic move to enhance its financial flexibility and explore growth opportunities, potentially impacting its market positioning and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025